Figure 1
From: Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells
Pretreatment with trastuzumab in HER-2-positive cells up-regulated caveolin-1 expression and improved T-DM1 drug efficacy. (A) Treatment of BT-474 cells with trastuzumab (10 μg/ml) induced caveolin-1 overexpression at 12 and 24 hours. (B) BT-474 cells pretreated with trastuzumab (TRA) for 24 hours were then treated with trastuzumab or T-DM1 for an additional 72 hours, and the cell viability was significantly decreased. Ctr: control group without treatment; TRA: trastuzumab. Statistical values with different letters were significantly different (P < 0.01). At least three independent experiments were performed for all quantifications. The western blots were derived under the same experimental conditions from the same cell lysates; the original full-length Western blot images are showed in Supplementary Figure S1.
